NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, Forecast & News

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) issued its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($2.59) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.35) by $0.24. The biopharmaceutical company earned $61.95 million during the quarter, compared to the consensus estimate of $63.89 million. Intercept Pharmaceuticals had a negative net margin of 143.09% and a negative return on equity of 495.47%. The firm's revenue for the quarter was up 31.8% on a year-over-year basis. During the same period in the previous year, the company posted ($2.18) EPS. View Intercept Pharmaceuticals' Earnings History.

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Intercept Pharmaceuticals.

Intercept Pharmaceuticals will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

18 equities research analysts have issued 12 month price targets for Intercept Pharmaceuticals' shares. Their forecasts range from $102.00 to $257.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $157.47 in the next twelve months. This suggests a possible upside of 65.8% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 4 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.

Media stories about ICPT stock have trended very negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Intercept Pharmaceuticals.

Intercept Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,910,000 shares, an increase of 8.1% from the January 15th total of 4,540,000 shares. Based on an average daily volume of 684,600 shares, the days-to-cover ratio is presently 7.2 days. Currently, 19.5% of the company's shares are short sold. View Intercept Pharmaceuticals' Current Options Chain.

Some companies that are related to Intercept Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Alibaba Group (BABA), NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Micron Technology (MU), Biogen (BIIB) and Celgene (CELG).

Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include First Trust Advisors LP (2.38%), Geode Capital Management LLC (1.10%), Pinnacle Associates Ltd. (0.53%), Jennison Associates LLC (0.52%), Charles Schwab Investment Management Inc. (0.50%) and Goldman Sachs Group Inc. (0.47%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, David Shapiro, Francesco Micheli, Gail Cawkwell, Jason Campagna, Keith Michael Gottesdiener, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.

ICPT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., First Trust Advisors LP, Peregrine Capital Management LLC, Rafferty Asset Management LLC, Spark Investment Management LLC, Schonfeld Strategic Advisors LLC, Man Group plc and Chicago Equity Partners LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David A Ford, David Shapiro, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro and Ryan T Sullivan. View Insider Buying and Selling for Intercept Pharmaceuticals.

ICPT stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Pictet Asset Management Ltd., California Public Employees Retirement System, Cubist Systematic Strategies LLC, Geode Capital Management LLC, W.E. Donoghue & Co. LLC, Bank of New York Mellon Corp and EAM Investors LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener, Luca Benatti, Mark Pruzanski and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ICPT stock can currently be purchased for approximately $94.99.

Intercept Pharmaceuticals has a market capitalization of $3.11 billion and generates $179.80 million in revenue each year. The biopharmaceutical company earns $-309,240,000.00 in net income (profit) each year or ($10.86) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.View Additional Information About Intercept Pharmaceuticals.

The official website for Intercept Pharmaceuticals is http://www.interceptpharma.com/.

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]